Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up – Time to Buy?

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s stock price gapped up prior to trading on Monday. The stock had previously closed at $4.55, but opened at $4.78. Gyre Therapeutics shares last traded at $5.0050, with a volume of 74,317 shares.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Gyre Therapeutics in a research report on Friday, August 7th. Wall Street Zen cut Gyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. Finally, Zacks Research upgraded shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 6th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce”.

Gyre Therapeutics Stock Down 6.1%

The stock’s 50-day simple moving average is $6.65 and its 200 day simple moving average is $6.96. The stock has a market capitalization of $495.10 million, a price-to-earnings ratio of -21.14 and a beta of 2.14.

Gyre Therapeutics (NASDAQ:GYRE) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Gyre Therapeutics had a negative net margin of 15.47% and a negative return on equity of 6.57%. The firm had revenue of $29.11 million during the quarter, compared to analyst estimates of $26.49 million. As a group, equities research analysts anticipate that Gyre Therapeutics, Inc. will post -0.61 earnings per share for the current year.

Institutional Investors Weigh In On Gyre Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Gyre Therapeutics in the 2nd quarter worth $6,550,000. SBI Securities Co. Ltd. lifted its holdings in shares of Gyre Therapeutics by 1.8% in the 3rd quarter. SBI Securities Co. Ltd. now owns 169,717 shares of the company’s stock worth $1,244,000 after buying an additional 2,967 shares during the period. Bank of New York Mellon Corp purchased a new position in Gyre Therapeutics in the second quarter valued at about $414,000. Dimensional Fund Advisors LP increased its holdings in Gyre Therapeutics by 131.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock worth $176,000 after buying an additional 14,365 shares during the period. Finally, Deutsche Bank AG acquired a new stake in Gyre Therapeutics during the second quarter valued at $118,000. 23.99% of the stock is currently owned by institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a biopharmaceutical company focused on developing therapies for fibrotic diseases, including pulmonary and liver fibrosis. The company’s lead development program is F351, also known as hydronidone, an investigational small-molecule therapy designed to inhibit the progression of fibrosis.

F351 is being evaluated in clinical programs for idiopathic pulmonary fibrosis and liver fibrosis associated with chronic liver disease, including nonalcoholic steatohepatitis-related fibrosis.